Omori, Shota
Harada, Hideyuki
Mori, Keita
Hisamatsu, Yasushi
Tsuboguchi, Yuko
Yoshioka, Hiroshige
Morinaga, Ryotaro
Daga, Haruko
Kurata, Takayasu
Takahashi, Toshiaki http://orcid.org/0000-0002-8188-2505
Article History
Received: 11 June 2021
Accepted: 18 July 2021
First Online: 8 September 2021
Change Date: 20 September 2021
Change Type: Update
Change Details: Springer Nature’s version of this paper was updated to include the supplementary materials.
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and the 1964 Helsinki declaration and its later amendments or with comparable ethical standards. This study was reviewed and approved by the certified review board of Shizuoka Cancer Center and registered with the Japan Registry of Clinical Trials on March 11, 2019 (trial no. jRCTs042180077).
: All patients provided written informed consent before enrollment.
: Shota Omori received honoraria from Taiho-Pharma, Chugai-Pharma, Daiichi-Sankyo, Amgen, AstraZeneca, Ono-Pharma, and Novartis outside the submitted work. Hideyuki Harada received honoraria from AstraZeneca, Chugai-Pharma, Daiichi-Sankyo, Novartis, Eli Lilly, Pfizer, and Brainlab outside the submitted work. Hiroshige Yoshioka received honoraria from Taiho-Pharma, Delta-Fly Pharma, Eli Lilly, Chugai-Pharma, AstraZeneca, Ono-Pharma, MSD, Novartis, Kyowa Hakko Kirin, Daiichi-Sankyo, Nippon Kayaku, Otsuka-Pharma, and Pfizer outside the submitted work. Haruko Daga received honoraria from Chugai-Pharma and Ono-Pharma and research funding from AstraZeneca, Chugai-Pharma, and Pfizer outside the submitted work. Takayasu Kurata received honoraria from AstraZeneca, Ono-Pharma, Bristol-Myers Squibb, Chugai-Pharma, Eli Lilly, and Boehringer Ingelheim, and MSD research funding from MSD, AstraZeneca, Eli Lilly, Takeda-Pharma, and Ono-Pharma outside the submitted work. Toshiaki Takahashi received honoraria from AstraZeneca, Boehringer Ingelheim, Chugai-Pharma, Eli Lilly, MSD, Ono-Pharma, Roche Diagnostics, and Pfizer, and research funding from AstraZeneca, Boehringer Ingelheim, Chugai-Pharma, Eli Lilly, Ono-Pharma, MSD, and Pfizer outside the submitted work. The other authors declare no conflicts of interest.